Advanced searches left 3/3

Elbasvir and Grazoprevir - Europe PMC

Summarized by Plex Scholar
Last Updated: 20 January 2022

* If you want to update the article please login/register

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).

Goals Grazoprevir/elbasvir and glecaprevir/pibrentasvir are both preferred therapy choices for patients with chronic liver disease C virus infection and a glomerular purification rate < 30 mL/min. Approaches The Germany Hepatitis C-Registry is a possible national real-world registry. The evaluation is based on 2773 patients with documented GFR at standard treated with grazoprevir/elbasvir, grazoprevir/elbasvir + ribavirin and glecaprevir/pibrentasvir. Outcomes An overall of 93 patients with GFR < 30 mL/min were treated with grazoprevir/elbasvir, grazoprevir/elbasvir + ribavirin, and glecaprevir/pibrentasvir. Conclusion In patients with chronic liver disease C and a standard GFR ≤ 30 mL/min grazoprevir/elbasvir and glecaprevir/pibrentasvir show a just as beneficial security account and antiviral efficacy and can both be recommended for real-life usage.

Source link: https://europepmc.org/article/MED/32956186


Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection.

A lot more options regarding the option of direct-acting antivirals are helpful for staying clear of specific constraints in dealing with liver disease C virus infection. We aimed to evaluate the efficacy and tolerability of grazoprevir/ elbasvir treatment in genotype-1b HCV-infected liver or kidney transplant recipients. In this stage 4, single-arm, open-label, multicenter test, patients obtained GZR 100mg/EBR 50mg everyday for 12 weeks. Patients with any HCV infection besides genotype-1b, liver decompensation, human immunodeficiency virus or liver disease B infection co-infection, a background of NS5A inhibitor exposure, or any extreme drug-drug communications were excluded. Only one patient ceased GZR/EBR treatment at 6 weeks posttreatment because of a treatment-unrelated damaging occasion; nonetheless, this patient continued to be accomplishing SVR12. The single-tablet program of GZR/EBR for 12 weeks is extremely efficient and well tolerated in GT-1b HCV-infected liver or kidney transplant recipients, and its DDIs are usually easy to take care of.

Source link: https://europepmc.org/article/MED/34902265

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions